Lisata Therapeutics advances certepetide, inks strategic alliances in Q3
Lisata Therapeutics Inc (NASDAQ:LSTA) has reported financial results for the third quarter, highlighting continued clinical progress for its lead...…
2,060$
-12,34%
Echtzeit-Aktienkurs Lisata Therapeutics Inc.
Bid:
Ask:
Nachrichten zur Lisata Therapeutics Inc. Aktie
Small cap wrap: Standard Uranium, Lisata Therapeutics, Alvopetro Energy, Happy Creek Minerals…
…
Lisata Therapeutics receives 2025 BioTech Breakthrough Award for Overall BioPharma Solution of the Year
Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has won the “Overall BioPharma Solution of the Year” in the fifth annual BioTech Breakthrough Awards...…
Lisata Therapeutics reports preclinical data showing certepetide’s potential to enhance cancer drug delivery
Lisata Therapeutics Inc (NASDAQ:LSTA) has reported promising preclinical results suggesting its iRGD cyclic peptide, certepetide, could enhance the...…
Lisata Therapeutics CEO discusses Catalent deal
Lisata Therapeutics Inc (NASDAQ:LSTA) CEO Dr David Mazzo talked with Proactive about the company’s new collaboration with Catalent, which reinforces…
Lisata Therapeutics CEO Dr David Mazzo on global product license deal with Catalent
…
Small cap wrap: GoviEx Uranium, Lisata Therapeutics, Bit Digital, Alvopetro Energy...
…
Lisata Therapeutics reveals encouraging preliminary data from pancreatic cancer treatment trial
Lisata Therapeutics Inc (NASDAQ:LSTA) announced what it called “encouraging” preliminary data from the pancreatic ductal adenocarcinoma (PDAC) cohort of the...…
Original-Research: Lisata Therapeutics Inc (von First Berlin Equity Research ...
^
Original-Research: Lisata Therapeutics Inc - from First Berlin Equity
Research GmbH
18.08.2025 / 13:41 CET/CEST
Dissemination of a Research,…
Lisata Therapeutics advances lead cancer drug, expects key trial results by year-end
Lisata Therapeutics Inc (NASDAQ:LSTA) said on Thursday it is making steady progress in advancing its pipeline of oncology drug candidates,…
Small cap wrap: Digi Power X, American Resources, OKYO Pharma, Lisata Therapeutics...
…
Lisata Therapeutics wraps up enrollment in promising pancreatic cancer study
Lisata Therapeutics Inc (NASDAQ:LSTA) and WARPNINE announced the completion of patient enrollment in the Phase 1b/2a iLSTA trial, which is…
Lisata Therapeutics and WARPNINE complete enrollment in iLSTA trial, share encouraging preliminary results
Lisata Therapeutics Inc (NASDAQ:LSTA) and WARPNINE announced the completion of patient enrollment in the Phase 1b/2a iLSTA trial, which is…
Small cap wrap: Lisata Therapeutics, Uranium American Resources, Nano One Materials...
…
Lisata Therapeutics expands IP with key patent covering certepetide’s chemical structure and uses
Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has been issued a new US composition of matter patent for its investigational…
Lisata Therapeutics and GATC advance AI-driven opioid use disorder therapy
Lisata Therapeutics Inc (NASDAQ:LSTA) CEO Dr David Mazzo talked with Proactive about the companys deepening collaboration with GATC Health. Mazzo…
Lisata Therapeutics reports encouraging data from ASCEND Cohort B evaluating certepetide in pancreatic cancer
Lisata Therapeutics Inc (NASDAQ:LSTA), in collaboration with the Australasian Gastro-Intestinal Trials Group and the NHMRC Clinical Trials Centre at the...…
Market movers: T-Mobile, Sunrun, First Solar, Lisata Therapeutics...
…
Lisata Therapeutics to lead development of opioid use disorder drug under expanded alliance
Lisata Therapeutics Inc (NASDAQ:LSTA) and GATC Health have expanded their strategic alliance aimed at accelerating and improving the success rate…
Lisata Therapeutics to lead development of OUD therapy under expanded alliance with GATC Health
Lisata Therapeutics Inc (NASDAQ:LSTA) and GATC Health have expanded their strategic alliance aimed at accelerating and improving the success rate…
Lisata eyes key trial milestones in 2025 as certepetide development gains momentum
Lisata Therapeutics Inc (NASDAQ:LSTA) said on Thursday it expects a data-rich year ahead as it advances multiple trials of its…
Lisata Therapeutics talks ADC breakthrough with Catalent
Lisata Therapeutics Inc earlier this week discussed the potential of certepetide in antibody-drug conjugate (ADC) applications through a new collaboration...…
Lisata Therapeutics CMO discusses potential for certepetide under Catalent license agreement
…
Lisata Therapeutics signs research license with Catalent
Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has entered into a research license agreement with Catalent to evaluate certepetide, its…
Lisata Therapeutics announces research license with Catalent
Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has entered into a research license agreement with Catalent to evaluate certepetide, its…
Original-Research: Lisata Therapeutics Inc (von First Berlin Equity Research ...
^Original-Research: Lisata Therapeutics Inc - from First Berlin EquityResearch GmbH01.04.2025 / 15:31 CET/CESTDissemination of a Research, transmitted by EQS News…
Original-Research: Lisata Therapeutics Inc (von First Berlin Equity Research ...
^
Original-Research: Lisata Therapeutics Inc - from First Berlin Equity
Research GmbH
01.04.2025 / 15:31 CET/CEST
Dissemination of a Research,…
Lisata Therapeutics CEO discusses AI drug discovery collaboration
Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo joined Proactive to discuss the company’s strategic collaboration with GATC Health, a leader…
Lisata Therapeutics expands drug discovery with GATC AI collaboration
…
Lisata Therapeutics partners with GATC Health to advance AI-driven drug development
Lisata Therapeutics Inc (NASDAQ:LSTA) has announced the first step of an intended multi-part strategic agreement with GATC Health, a leading…
Lisata Therapeutics CEO: 2025 to be ‘data-rich’ as certepetide trials progress
Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazza told investors that he expects 2025 to be a “data-rich year” in a…
Original-Research: Lisata Therapeutics Inc (von First Berlin Equity Research ...
^
Original-Research: Lisata Therapeutics Inc - from First Berlin Equity
Research GmbH
29.01.2025 / 09:50 CET/CEST
Dissemination of a Research,…
Original-Research: Lisata Therapeutics Inc (von First Berlin Equity Research ...
^Original-Research: Lisata Therapeutics Inc - from First Berlin EquityResearch GmbH29.01.2025 / 09:50 CET/CESTDissemination of a Research, transmitted by EQS News…
Lisata Therapeutics CEO discusses recent pancreatic cancer trial milestones
Lisata Therapeutics Inc (NASDAQ:LSTA) joined Proactive to discuss the latest updates from the compays pancreatic cancer trials. The company recently...…
Lisata Therapeutics CEO David Mazzo on ASCEND and iLSTA trial results
…
Lisata Therapeutics and WARPNINE unveil positive preliminary results from pancreatic cancer trial
Lisata Therapeutics Inc (NASDAQ:LSTA) and WARPNINE have announced promising preliminary results from their Phase 1b/2a iLSTA trial, which is evaluating...…
Lisata Therapeutics unveils encouraging preliminary data from Phase 2 pancreatic cancer trial
Lisata Therapeutics Inc (NASDAQ:LSTA) has reported encouraging preliminary data for Cohort A of its ongoing ASCEND Phase 2 trial. The…
Original-Research: Lisata Therapeutics Inc (von First Berlin Equity Research ...
^
Original-Research: Lisata Therapeutics Inc - from First Berlin Equity
Research GmbH
21.01.2025 / 13:55 CET/CEST
Dissemination of a Research,…
Original-Research: Lisata Therapeutics Inc (von First Berlin Equity Research ...
^Original-Research: Lisata Therapeutics Inc - from First Berlin EquityResearch GmbH21.01.2025 / 13:55 CET/CESTDissemination of a Research, transmitted by EQS News…
Beat the Market the Zacks Way: SoFi Technologies, Lisata Therapeutics, AutoZone in Focus
Our time-tested methodologies helped investors navigate the market well last week. Here are some of our key performance data from…
Lisata Therapeutics advances certepetide with trial enrollment milestone and new diagnostic partnership
Lisata Therapeutics Inc (NASDAQ:LSTA) shares were reacting positively this week after the company announced further developments for its lead...…
Lisata Therapeutics completes patient enrollment for CENDIFOX trial
Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has completed patient enrollment in all three cohorts of its Phase 1b/2a CENDIFOX…
Lisata Therapeutics completes patient enrollment for solid tumor cancer trial
Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has completed patient enrollment in all three cohorts of its Phase 1b/2a CENDIFOX…
Lisata Therapeutics and Kuva Labs to collaborate on cancer imaging solution
Lisata Therapeutics Inc (NASDAQ:LSTA) has announced a collaboration and license agreement with Kuva Labs, a wholly owned subsidiary of Mi2…
Lisata Therapeutics named ‘Specialized BioTherapeutics Company of the Year’ at 2024 BioTech Breakthrough Awards
Lisata Therapeutics Inc (NASDAQ:LSTA) has been awarded the title of ‘Specialized BioTherapeutics Company of the Year’ at the 2024 BioTech…
Lisata Therapeutics wins BioTech Breakthrough award
Lisata Therapeutics Inc (NASDAQ:LSTA) has been awarded the title of ‘Specialized BioTherapeutics Company of the Year’ at the 2024 BioTech…
Lisata Therapeutics CEO discusses pancreatic cancer trial progress and new collaborations
Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo joined Proactive to talk about the latest updates on its clinical trials and…
Lisata Therapeutics CEO David Mazzo on Q3 results; updates on key clinical trials and partnerships
…
Lisata Therapeutics advances clinical trials in Q3 ahead of data-rich 2025
Lisata Therapeutics Inc (NASDAQ:LSTA) reported significant advancements across its clinical portfolio in the third quarter, with multiple key data readouts...…
Lisata Therapeutics and Valo Therapeutics partner in preclinical study on cancer immunotherapy
Lisata Therapeutics Inc (NASDAQ:LSTA), the US-based clinical-stage pharmaceutical company, and Finnish immunotherapy developer Valo Therapeutics Oy have...…